Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biofrontera Inc BFRI

Healthcare
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial... see more

Recent & Breaking News (NDAQ:BFRI)

Biofrontera Inc. Enters into Agreements to Purchase Options of Biofrontera AG

GlobeNewswire October 31, 2022

Biofrontera Inc. Names Fred Leffler as Chief Financial Officer

GlobeNewswire October 24, 2022

Biofrontera Inc. to Present at the LD Micro Main Event XV Investor Conference

GlobeNewswire October 20, 2022

Biofrontera Inc. to Sponsor the 2022 Fall Clinical Dermatology Conference

GlobeNewswire October 18, 2022

Biofrontera Inc. Adopts Limited Duration Shareholder Rights Plan

GlobeNewswire October 14, 2022

BIOFRONTERA INC. TO PARTICIPATE IN RENMARK'S VIRTUAL NON-DEAL ROADSHOW SERIES ON FRIDAY OCTOBER 14, AND TUESDAY OCTOBER 18, 2022

GlobeNewswire October 12, 2022

Biofrontera Inc. Announces Preliminary Product Revenues for the Third Quarter of 2022

GlobeNewswire October 5, 2022

Biofrontera Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference

GlobeNewswire September 29, 2022

Biofrontera Inc.'s Marketing Campaign and Website for Ameluz Won 2022 PM360 Trailblazer Awards

GlobeNewswire September 26, 2022

Biofrontera Inc. Names Gerard DiGirolamo as National Sales Director

GlobeNewswire September 13, 2022

Biofrontera Inc. Announces Notice of Allowance for Nanoemulsion Composition-of-Matter U.S. Patent

GlobeNewswire September 6, 2022

Biofrontera Inc.'s Leslie Hopkins Named PM360 Trailblazer 2022 Brand Champion for Dermatology

GlobeNewswire August 18, 2022

Biofrontera Inc. Reports Second Quarter 2022 Financial Results and Provides a Business Update

GlobeNewswire August 12, 2022

Biofrontera Inc. to Report Second Quarter Financial Results on August 12, 2022

GlobeNewswire August 4, 2022

Biofrontera Inc. Announces Patent in Australia for Novel Illumination Protocols Granted to Biofrontera Bioscience GmbH

GlobeNewswire August 1, 2022

Biofrontera Inc. Announces Exercise of Existing Warrants and Issuance of Warrants in Private Placement

GlobeNewswire July 27, 2022

Biofrontera Inc. Announces Preliminary Product Revenues for the Second Quarter of 2022

GlobeNewswire July 12, 2022

Biofrontera, Inc. Recognized for Rapid Sales Growth, Innovative Therapies and Marketing Excellence

GlobeNewswire June 9, 2022

Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference

GlobeNewswire May 31, 2022

New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera's Ameluz®

GlobeNewswire May 24, 2022